ClinicalTrials.gg
CompletedNCT03733990Updated Apr 2, 2025Results posted

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)

A Phase 1/2 interventional study of FP-1305 (bexmarilimab) in Cancer, sponsored by Faron Pharmaceuticals Ltd. Completed at 11 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Faron Pharmaceuticals Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
216
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity.

The patients with advanced melanoma, uveal melanoma, cholangiocarcinoma, gallbladder cancer, ER+ breast, gastric, ovarian, pancreatic, colorectal, liver or anaplastic thyroid cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator's existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 216 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Faron Pharmaceuticals Ltd is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects must meet all of the following inclusion criteria to be eligible for participation in the clinical trial:

  1. Written
  2. Aged ≥ 18 years male or female
  3. Tumour sample should be collected during screening period. If a recent tumour obtained within six months before the date of consent is available (or older, as agreed on a case by case basis with the sponsor), that may be used. At the discretion of the sponsor, the tumour sample may be optional for certain subjects in Part III
  4. > 12 weeks
  5. confirmed advanced (inoperable or ) without standard therapeutic options available:

    • Hepatocellular carcinoma
    • Gallbladder cancer or intra- or extrahepatic cholangiocarcinoma
    • Colorectal adenocarcinoma
    • Serous poorly differentiated (Grade 3) ovarian adenocarcinoma or undifferentiated ovarian cancer
    • Pancreatic ductal adenocarcinoma
    • Immunotherapy (IO) cutaneous melanoma (progression either on or after programmed cell death protein-1 ()/programmed cell death ligand-1 (PD-L1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody therapy)
    • Uveal melanoma in Parts II and III
    • Gastric adenocarcinoma (including adenocarcinoma of the distal esophagus / GE junction) in Parts II and III
    • ER+ breast cancer in Parts II and III
    • Anaplastic thyroid cancer in Parts II and III
  6. performance status 0 or 1
  7. in Parts II and III
  8. Adequate bone marrow, liver and kidney function defined as Blood white blood cell ≥ lower limit of normal Blood ≥ 1x10(9)/L Blood count ≥ 100x10(9)/L, for HCC ≥ 50x10(9)/L Blood ≥ 9.0 g/dL > 40 mL/min calculated by Cockcroft-Gault formula ≤ 3 X (≤ 5 x ULN when HCC or hepatic metastases are present) ALT ≤ 3 X ULN (≤ 5 x ULN when HCC or hepatic metastases present) ≤ 1.5 X ULN Albumin ≥ 3.0 g/dL The most recent measurements taken during the screening period must be within the required limits for the patient to be considered eligible (i.e. criteria met once during the screening period are not sufficient if there are more recent measurements available that are not within the required limits. It is however acceptable to repeat measurements if the initial measurements or subsequent measurements taken during the screening period are not within the required limits; the patient is eligible providing that the newest measurements are within the required limits). However, once a subject is out of the screening period, and has had eligibility confirmed and been enrolled, the pre-dose laboratory assessments are not subjected to inclusion criteria limits, but only for investigators assessment of subject safety.
  9. Women of must have a negative pregnancy test in serum prior to trial entry
  10. Women of child-bearing potential and men who have partners of child-bearing potential must be willing to practise highly effective for the duration of the trial and for three months after the completion of treatment

Exclusion Criteria;

  1. Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than five half-lives from a small molecule targeted therapy or oral anticancer chemotherapy before the first IMP administration
  2. Any immunotherapy within preceding 6 weeks from the first IMP administration
  3. therapy or major surgery within 4 weeks from the date of consent
  4. Active clinically serious infection > Grade 2 version 5.0 (Appendix 5 - Common Toxicity Criteria Gradings) within preceding 2 weeks from the date of consent
  5. Subject has not recovered from the previous therapies to Grade ≤ 1 severity as classified by the NCI-CTCAE version 5.0 (except Grade ≤ 2 alopecia, neuropathy or thyroid disorders)
  6. Pregnant or lactating women
  7. History of second malignancy except for non-melanotic skin cancer, cervical carcinoma in situ or superficial bladder cancer, or any other malignancy treated previously with curative intent and more than three years without relapse
  8. Evidence of severe or uncontrolled systemic diseases, congestive cardiac failure (NYHA) class 2 (Appendix 7 - NYHA classification), Myocardial Infarction (MI) within 6 months or laboratory finding that in the view of the investigator makes it undesirable for the subject to participate in the trial
  9. Any medical condition that the Investigator considers significant to compromise the safety of the subject or that impairs the interpretation of IMP toxicity assessment
  10. Confirmed infection
  11. Symptomatic cytomegalovirus infection
  12. Subjects with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia)
  13. The subject requires systemic or other treatment
  14. Subjects with organ transplants
  15. Subjects in dialysis
  16. Use of Live (attenuated) vaccines for 30 days prior to the start of study treatment, during treatment, and until last visit
  17. Subject is unwilling or unable to comply with treatment and trial instructions
  18. Subjects with known to the IMP or any of the pharmaceutical ingredients

Specific Additional Exclusion Criteria for Hepatobiliary Cancers

  1. Any ablative therapy (Radio Frequency Ablation or Percutaneous Ethanol Injection) for HCC (this should not exclude subjects if target lesion(s) have not been treated and occurred > 6 weeks prior trial entry)
  2. Hepatic encephalopathy
  3. Ascites refractory to diuretic therapy
  4. score ≥ 7
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    FP-1305 (bexmarilimab) 0.3 mg/kg

    Part I, Dose-escalation FP-1305 0.3 mg/kg is administered in Q3W intervals

    Biological: FP-1305 (bexmarilimab)

  • Experimental
    FP-1305 (bexmarilimab) 1 mg/kg

    Part I and II, Dose-escalation FP-1305 1 mg/kg is administered in Q3W, Q2W or Q1W intervals

    Biological: FP-1305 (bexmarilimab)

  • Experimental
    FP-1305 (bexmarilimab) 3 mg/kg

    Part I and II, Dose-escalation FP-1305 3 mg/kg is administered in Q3W, Q2W or Q1W intervals

    Biological: FP-1305 (bexmarilimab)

  • Experimental
    FP-1305 (bexmarilimab) 10 mg/kg

    Part I and II, Dose-escalation FP-1305 10 mg/kg is administered in Q3W, Q2W or Q1W intervals

    Biological: FP-1305 (bexmarilimab)

  • Experimental
    FP-1305 (bexmarilimab) 0.1 mg/kg

    Part I Dose-escalation FP-1305 0.1 mg/kg is administered in three-week intervals

    Biological: FP-1305 (bexmarilimab)

  • Experimental
    FP-1305 (bexmarilimab) 30 mg/kg

    Part II Dose-escalation FP-1305 30 mg/kg is administered in Q3W, Q2W or Q1W intervals

    Biological: FP-1305 (bexmarilimab)

Interventions

  • The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.

    Also known as: bexmarilimab

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT) in the Trial Subjects.

    Tolerable dose(s) will be determined by the TITE-CRM based on the occurrence/non-occurrence of dose limiting toxicities in the trial subjects.

    Time frame: Up to one year

  2. Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)

    Number of adverse events and serious adverse events. Adverse events are collected, graded and reported according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

    Time frame: approximately 4 years and 9 months

  3. The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.

    The objective response rate (ORR) to the treatment will be determined by tumour imaging (tumor size) according to RECIST v.1.1. Results from each tumour type, dose level and dosing frequency are reported separately.

    Time frame: approximately 4 years and 9 months

  4. The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.

    The disease control rate (DCR) response to the treatment will be determined by tumour imaging (tumor size) according to RECIST v.1.1 are presented by cycles and by doing so there is no difference in the definition of DCR and Clinical Benefit Rate (CBR)

    Time frame: approximately 4 years and 9 months

07

Results

Posted Apr 2, 2025

Participant flow

Participant flow — Overall Study
MilestoneFP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kg
Started13130411859
Completed13130411859
Not completed000000

Outcome measures

PrimaryDose Limiting Toxicities (DLT) in the Trial Subjects.

Tolerable dose(s) will be determined by the TITE-CRM based on the occurrence/non-occurrence of dose limiting toxicities in the trial subjects.

Time frame:
Up to one year
Reported as:
Number · DLT
Dose Limiting Toxicities (DLT) in the Trial Subjects.
DLTFP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kg
Dose Limiting Toxicities (DLT) in the Trial Subjects.000000
PrimaryNumber of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)

Number of adverse events and serious adverse events. Adverse events are collected, graded and reported according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

Time frame:
approximately 4 years and 9 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)
ParticipantsFP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kg
Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)13122381759
PrimaryThe Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.

The objective response rate (ORR) to the treatment will be determined by tumour imaging (tumor size) according to RECIST v.1.1. Results from each tumour type, dose level and dosing frequency are reported separately.

Time frame:
approximately 4 years and 9 months
Reported as:
Count of participants · Participants
The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.
ParticipantsFP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kg
The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.100000
PrimaryThe Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.

The disease control rate (DCR) response to the treatment will be determined by tumour imaging (tumor size) according to RECIST v.1.1 are presented by cycles and by doing so there is no difference in the definition of DCR and Clinical Benefit Rate (CBR)

Time frame:
approximately 4 years and 9 months
Reported as:
Count of participants · Participants
The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.
ParticipantsFP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kg
The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.1204201

Adverse events

Collected over Approximately 4 years and 11 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FP-1305 (Bexmarilimab) 0.3 mg/kg0/13 (0%)1/13 (7.7%)13/13 (100%)
FP-1305 (Bexmarilimab) 1 mg/kg12/130 (9.2%)57/130 (43.8%)122/130 (93.8%)
FP-1305 (Bexmarilimab) 3 mg/kg3/41 (7.3%)13/41 (31.7%)38/41 (92.7%)
FP-1305 (Bexmarilimab) 10 mg/kg3/18 (16.7%)10/18 (55.6%)17/18 (94.4%)
FP-1305 (Bexmarilimab) 0.1 mg/kg0/5 (0%)3/5 (60%)5/5 (100%)
FP-1305 (Bexmarilimab) 30 mg/kg0/9 (0%)4/9 (44.4%)9/9 (100%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventFP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kg
AscitesGastrointestinal disorders0/135/1302/411/182/50/9
PyrexiaGeneral disorders0/132/1301/410/181/50/9
General physical health deteriorationGeneral disorders0/132/1300/410/181/50/9
Infected seromaInfections and infestations0/130/1300/410/181/50/9
Adrenocortical insufficiency acuteEndocrine disorders0/130/1300/410/180/51/9
Intestinal obstructionGastrointestinal disorders0/132/1300/410/180/51/9
CholestasisHepatobiliary disorders0/131/1300/412/180/50/9
BacteraemiaInfections and infestations0/130/1300/410/180/51/9
DyspnoeaRespiratory, thoracic and mediastinal disorders0/130/1300/410/180/51/9
Respiratory syncytial virus infectionInfections and infestations1/130/1300/410/180/50/9
Most frequent other events
Showing 10 of 16
Most frequent other events
EventFP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kg
General disorders and administration site conditionsGeneral disorders8/1357/13016/4111/183/56/9
Nervous system disordersNervous system disorders3/1314/1306/411/180/56/9
Gastrointestinal disordersGastrointestinal disorders7/1349/13020/415/182/55/9
Metabolism and nutrition disordersMetabolism and nutrition disorders3/1336/13010/418/181/50/9
Infections and infestationsInfections and infestations2/1316/1307/411/182/52/9
InvestigationsInvestigations4/1340/13010/416/182/53/9
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders5/1325/13012/415/181/50/9
Blood and lymphatic system disordersBlood and lymphatic system disorders2/1332/13011/416/181/52/9
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders4/1321/1304/413/181/51/9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps)0/139/1304/412/181/50/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)FP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kgTotal
<=18 years0000000
Between 18 and 65 years39125938139
>=65 years10391692177
Age, Continuous
Age, Continuous(years)FP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kgTotal
Mean67.15 ± 5.44459.67 ± 10.56361.80 ± 11.02361.44 ± 13.32157.60 ± 16.95057.33 ± 6.69060.53 ± 10.787
Sex: Female, Male
Sex: Female, Male(Participants)FP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kgTotal
Female86019656104
Male570221203112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kgTotal
Asian1101003
White10106331258174
Not reported0510006
Other218750133
Region of Enrollment
Region of Enrollment(participants)FP-1305 (Bexmarilimab) 0.3 mg/kgFP-1305 (Bexmarilimab) 1 mg/kgFP-1305 (Bexmarilimab) 3 mg/kgFP-1305 (Bexmarilimab) 10 mg/kgFP-1305 (Bexmarilimab) 0.1 mg/kgFP-1305 (Bexmarilimab) 30 mg/kgTotal
Netherlands216840131
United States0401005
Finland6431235372
United Kingdom521830037
France026540035
Spain020830536
08

Study locations

11 sites
  • The University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229-3901, United States
  • Clinical Research Institute HUCH Ltd
    Helsinki, 00290, Finland
  • Oulu University Hospital
    Oulu, 90220, Finland
  • Tampere University Hospital
    Tampere, 33520, Finland
  • Turku University Hospital
    Turku, 20520, Finland
  • The Institut Gustave Roussy
    Villejuif, 94805, France
  • Erasmus University Medical Center Rotterdam
    Rotterdam, 3015 GD, Netherlands
  • START Madrid - CIOCC Hospital HM Sanchinarro
    Madrid, 28050, Spain
  • The Royal Marsden NHS Foundation Trust
    Sutton, Surrey SM2 5PT, United Kingdom
  • Queen Elizabeth Hospital Birmingham
    Birmingham, B15 2GW, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Hollmen M, Maksimow M, Rannikko JH, Karvonen MK, Vainio M, Jalkanen S, Jalkanen M, Mandelin J. Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers. Mol Cancer Ther. 2022 Jul 5;21(7):1207-1218. doi: 10.1158/1535-7163.MCT-21-0840. PubMed 35500016 ↗
  • Virtakoivu R, Rannikko JH, Viitala M, Vaura F, Takeda A, Lonnberg T, Koivunen J, Jaakkola P, Pasanen A, Shetty S, de Jonge MJA, Robbrecht D, Ma YT, Skytta T, Minchom A, Jalkanen S, Karvonen MK, Mandelin J, Bono P, Hollmen M. Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clin Cancer Res. 2021 Aug 1;27(15):4205-4220. doi: 10.1158/1078-0432.CCR-20-4862. Epub 2021 Jun 2. PubMed 34078651 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Sep 2023, 57 months.

Results were first posted in Apr 2025, 1 year 6 months after primary completion.

Of 195 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 57 months is close to that.

Counting every sponsor, half of 297 studies reached it within 60 months; a quarter within 39 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2018
First posted
Nov 7, 2018
StartActual
Dec 3, 2018
Primary completionActual
Sep 6, 2023
CompletionActual
Oct 31, 2023
Results first posted
Apr 2, 2025
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03733990
Lead sponsor
Faron Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Nov 7, 2018
Start date
Dec 3, 2018
Primary completion
Sep 6, 2023
Completion
Oct 31, 2023
Results posted
Apr 2, 2025
Last update
Apr 2, 2025

Study contacts

Petri Bono, MD, PhD
principal investigator · Terveystalo Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bexmarilimab

Start the discussion